Titanium Reinforced d-PTFE Membrane Versus Collagen Membrane For Guided Bone Regeneration

Alveolar Ridge Enlargement Clinical Trial

Official title:

A Randomized Controlled Trial Comparing Titanium Reinforced d-PTFE Membrane to Collagen Membrane for Guided Bone Regeneration at Single Tooth Sites in the Premaxilla: a Clinical, CBCT and Histomorphometric Analysis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05426616
• Other study ID #: BC-11825
• Status: Recruiting
• Phase: N/A
• Start date: June 1, 2022
• Est. completion date: December 31, 2028

Study information

• Verified date: July 2023
• Source: University Ghent
• Contact: Jan Cosyn, Professor
• Phone: 093324017
• Email: jan.cosyn[@]ugent.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

After tooth extraction, shrinkage of the bone is expected with 50% reduction of alveolar width. Patients at least 3months after tooth extraction and in need of single oral implant placement in the anterior maxilla with both neighboring teeth present, were invited to participate in an inter-subject RCT if insufficient residual alveolar bone was left for proper implant placement. Guided bone regeneration has been used to recreate bone volume. A combination of xenogenous bone (Creos Xenogain , Nobel Biocare AB, Göteborg, Sweden) and autologous bone chips in a 1:1 ratio, is protected by a membrane fixated in the bone. A resorbable, non-stable membrane (Creos Xenoprotect, Nobel Biocare AB, Göteborg, Sweden) or non-resorbable titanium reinforced d-PTFE membrane (Creos Syntoprotect , Nobel Biocare AB, Göteborg, Sweden) can be used. This study aims to compare the effectivity of the two membranes by measuring changes in bone dimensions. The resorbable membrane has the advantage that it does not need to be removed, whereas the titanium reinforced membrane can protect the rebuilt volume better against external forces. Patients start to take systemic antibiotics (Amoxicilline 1g) and anti-inflammatory medication (ibuprofen 600 mg) 1h pre-operatively. Following local anesthesia (Septanest special, Septodont, Saint Maur des Fossés, France) and oral disinfection (Corsodyl mouth rinse, GSK, Wavre, Belgium), a large mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space and at the distal aspect of the second neighboring tooth. The flap extends to the base of the alveolar process to allow full access. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector (NeoBiotech, Guro-gu Seoul, Republic of Korea). DBBM particles (Xenogain, Nobel Biocare, Göteborg, Sweden) soaked in blood are mixed with autogenous bone chips to a ratio of 1/1. After having made multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied. An individualized collagen membrane (Xenoprotect, Nobel Biocare, Göteborg, Sweden) or a non-resorbable titanium reinforced d-PTFE membrane is attached on top using membrane fixation pins. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved with horizontal mattress 4/0 titanium reinforced d-PTFE sutures and single 6/0 monofilament sutures. Patients continue the intake of antibiotics and anti-inflammatory medication for 7 days and use an oral mouthrinse during 2 weeks. Sutures are removed after 2 weeks, and an implant is installed after 9 months following 3D implant planning. A sample size calculation indicated 17 patients to be included per group. To compensate for one drop-out, 18 patients would be treated with collagen membrane and 18 would be treated with titanium reinforced d-PTFE. Changes in horizontal bone dimensions over time is the primary outcome. Prior to surgery, immediately after GBR, at 9 months, at 3 years and 5 years a CBCT is taken. Every CBCT is superimposed to the baseline CBCT in designated software and horizontal buccal bone dimensions are measured. Secondary outcomes include - Membrane exposure - Intrasurgical changes in bone crest width over time - Intrasurgical assessment of bone quality at implant placement at the palatal, midcrestal and buccal aspect - Need for re-grafting at implant placement - Need for soft tissue grafting at implant placement - Need for augmentation of keratinized mucosa at implant placement - Volumetric increase in buccal bone at 3 and 5 years - Peri-implant health at 3 and 5 years by means of intra-oral radiograph - Esthetic outcomes at 3 and 5 years - Histomorphometric analysis on 20 cases (10 per group)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: December 31, 2028
• Est. primary completion date: December 31, 2028
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• good oral hygiene defined as full-mouth plaque score = 25% (O'Leary et al. 1972)
• presence of a single tooth gap in the anterior maxilla (15-25) with both neighboring teeth present
• failing tooth at least 3 months earlier removed

Exclusion Criteria:

• systemic diseases
• smoking; (history of) periodontal disease
• untreated caries lesions
• pregnancy (will be explicitly asked)

Related Conditions & MeSH terms

• Alveolar Ridge Enlargement
• Hypertrophy

Intervention

Device:
• collagen membrane (Creos Xenoprotect , Nobel Biocare AB, Göteborg, Sweden)
A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After having made multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied. An individualized collagen membrane is attached on top using membrane fixation pins. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved.
• titanium reinforced d-PTFE membrane (Creos Syntoprotect , Nobel Biocare AB, Göteborg, Sweden)
A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied.A titanium reinforced d-PTFE membrane is attached on top using membrane fixation pins. Care is taken to leave a distance of at least 1 mm between the membrane and neighboring teeth. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved. The membrane is removed after 9 months, prior to implant placement.

Locations

Country	Name	City	State
Belgium	Universitair Ziekenhuis Gent	Gent	Oost-Vlaanderen
Belgium	Centrum voor Parodontologie en Orale Implantologie	Zottegem	Oost-Vlaanderen
Belgium	Parodonto	Zwijnaarde	Oost-Vlaanderen

Sponsors (1)

Lead Sponsor	Collaborator
University Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in horizontal bone dimensions over time	At T0, t1, t2, t3 and t4 a CBCT is taken. Every CBCT is superimposed to the baseline CBCT in designated software and horizontal buccal bone dimensions are measured at 1 mm, 3 mm, 5 mm, 7 mm and 9 mm from the crest. The changes from baseline in horizontal bone dimensions at the different levels is calculated.	baseline = t0, immediately after GBR = t1, at 9 months= t2, 3 years = t3 and 5 years=t4
Secondary	Membrane exposure	Wound dehiscence after GBR could expose the membrane. Clinically assessment if the membrane is coming exposed through the mucosa during the healing period of 9months after placement, results in a % of cases with membrane exposure.	During the 9 months of healing after GBR.
Secondary	Intrasurgical changes in bone crest width over time	Measurement of the bone crest width intrasurgically, after mucoperiosteal flap preparation.	Baseline, after GBR and 9 months after GBR during implant placement procedure.
Secondary	Bone type: clinician perception (hand feel resistance)	Classification by Misch. Tactile sense of the surgeon in the assessment of bone density, groups (D1-D4). D1 bone type = homogenous dense cortical. D2 = combination of dense-to-porous cortical bone on the crest and trabecular bone from 40% to 60% on the inside. D3 = thinner porous cortical bone on the crest and fine trabecular bone within the ridge. D4 = bone has the least trabecular density with little or no cortical crestal bone.	t2 = 9 months after GBR, at implant placement
Secondary	Bone dimensions vertically and horizontally	Bone volume assessment for the ideal restorative driven position of the implant after 9 months of healing, reporting if insufficient bone was leading to additional bone grafting simultaneously at the time of implant placement.; Edentulous bone ridge classification followed three-dimensional (3D) quantity of alveolar bone shape and volume based on CBCT measurements. (UCLA) Classification: Type I: sufficient alveolar shape for implants, Type II: insufficient alveolar bone on the buccal site, Type III: knife edge shape with sufficient alveolar bone height, Type IV: insufficient alveolar bone height.	t2 = 9 months after GBR, at implant placement
Secondary	Buccal soft tissue thickness	Buccal concavity after resorption of the soft tissue, can cause additional need for soft tissue augmentation procedure. The need for soft tissue augmentation will be scored by the clinician. The thickness of the soft tissues was measured (in mm) at t2 (9months after GBR), t3 (3 years) and T4 (5years) perpendicular to the long axis of the implant. Buccal soft tissue thickness was measured from the bone-soft tissue interface to the buccal soft tissue outline at the same levels as horizontal bone dimensions.	t2 = 9 months after GBR, at implant placement
Secondary	Buccal keratinized soft tissue width	The width of the keratinized soft tissues buccally was measured clinically (in mm) at t2 (9months after GBR), t3 (3 years) and T4 (5years) from the gingival margin to mucogingival junction. Minimally 3 mm provides a prosthetic friendly environment, allows oral hygiene maintenance, resists recession, and enhances esthetic blending. If less than 3mm, additional soft tissue grafting can be indicated.	t2 = 9 months after GBR, at implant placement
Secondary	Volumetric changes in buccal bone at 3 and 5 years	Volumetric measurement with CBCT by superimposed the images in specialized software (OnDemand3D, Cybermed Inc., Seoul, South-Korea). Changes in bone volume are calculated by subtracting.	baseline = t0, immediately after GBR = t1, at 9 months= t2, 3 years = t3 and 5 years=t4
Secondary	Peri-implant health	Evaluation by means of intra-oral radiograph of bone level.	At 3 and 5 years
Secondary	Pink Esthetic Score	The PES awards 7 parameters: mesial papilla, distal papilla, soft tissue level, soft tissue contour, alveolar process deficiency, soft tissue colour, soft tissue texture. Each parameter is assessed with a 0-1-2 score, yielding a PES score ranging from 0 (worst aesthetic outcome) to 14 (perfect aesthetic outcome).	At 3 and 5 years
Secondary	Histomorphometric analysis	On 20 cases (10 per group), with a trepan bur, bone samples are removed and collected from implant site at 9 months right before implant placement, for measurements: Vital bone fraction, biomaterial fraction, connective tissue fraction and cell counts.	t2 = 9 months after GBR, at implant placement